Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 23/10/2025

3,520 CHF (+0,28%)

(+0,28%) 23/10/2025

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d 0,28%
1 week1w -9,51%
1 maand1m -5,25%
3 maanden3m 25,27%
6 maanden6m 207,16%
1 jaar1j 212,06%
5 jaar5j -85,07%

donderdag 30 oktober 2025, 07:00

Kwartaalcijfers (3de kwartaal)

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

10 oktober 2025 · Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability · Persbericht

9 oktober 2025 · Idorsia launches an offering of registered shares – to fund the company to overall profitability · Persbericht

22 september 2025 · Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China · Persbericht

19 september 2025 · Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension · Persbericht

10 september 2025 · Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025 · Persbericht

8 september 2025 · Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025 · Persbericht

5 september 2025 · Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension · Persbericht

3 september 2025 · Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call · Persbericht

1 september 2025 · Idorsia furthers the science of sleep and insomnia at World Sleep 2025 · Persbericht

28 augustus 2025 · Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe